Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

GW9662

Catalog No: tcsc1102

Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
22978-25-2

Formula:
$C_{13}H_9ClN_2O_3$

Pathway:
Cell Cycle/DNA Damage

Target:
PPAR

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 100 mg/mL (361.43 mM); H2O :

Observed Molecular Weight:
276.68

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

GW9662 is a potent and selective **PPARγ** antagonist with an **IC_{50}** of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPARδ, respectively.

IC50 & Target: IC50: 3.3 nM/32 nM/2 μM (PPARγ/α/δ)[1]

In Vitro: GW9662 inhibits radioligand binding to PPARγ, PPARα, and PPARδ with pIC_{50}s of 8.48±0.27 (IC_{50}=3.3 nM; n=10), 7.49±0.17 (IC_{50}=32 nM; n=9), and 5.69±0.17 (IC_{50}=2000 nM; n=3), respectively. GW9662 has nanomolar IC_{50} versus PPARγ and is 10- and 600-fold less potent in binding experiments using PPARα and PPARδ, respectively. In cell-based reporter assays, GW9662 is a potent and selective antagonist of full-length PPARγ[1]. Co-treatment with both 50 μM Rosiglitazone and 10 μM GW9662 results in statistically lower viable cell numbers after 7 days when compared to treatment with either 50 μM rosiglitazone (P=0.001) or 10 μM GW9662 (P=0.01) alone[2].

In Vivo: Bone marrow (BM) nucleated cell counts in both BADGE- and GW9662(1 mg/kg, i.p.)-treated mice are significantly higher than counts in the aplastic anemia (AA) group[3]. GW9662 (1 mg/kg, i.p.) largely attenuates the renoprotective effects of Lipopolysaccharide (LPS) in the rat[4].